These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30047799)

  • 81. Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis.
    Toshikuni N
    Gut Liver; 2017 May; 11(3):335-348. PubMed ID: 27840363
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
    Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options.
    Loggi E; Vukotic R; Andreone P
    Expert Rev Anti Infect Ther; 2018 Nov; 16(11):833-838. PubMed ID: 30336699
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Extrahepatic and Intrahepatic Malignancies in Patients With HCV Who Achieve an SVR With Directly Acting Antiviral Agents: Should We be Concerned that DAA Therapy Contributed to this Phenomenon?
    Gaglio PJ
    J Clin Gastroenterol; 2017 Sep; 51(8):657-658. PubMed ID: 28796002
    [No Abstract]   [Full Text] [Related]  

  • 85. Behind the Decrease of Liver Stiffness After Successful Hepatitis C Virus Eradication with Direct-Acting Antiviral Agents.
    Giuffrè M; Masutti F; Maria Crosato I; Luzzati R; Saveria Crocè L
    Turk J Gastroenterol; 2022 Feb; 33(2):169-170. PubMed ID: 35238783
    [No Abstract]   [Full Text] [Related]  

  • 86. [Chronic hepatitis C: achievement, challenge and strategy to eliminate as a public health threat].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):161-168. PubMed ID: 29804387
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Letter to the Editor: Recurrent Cryoglobulinemic Vasculitis in the Era of Direct-Acting Antivirals: A Story Beyond Sustained Virological Response 12.
    Roy A; Dhiman RK
    Hepatology; 2021 Nov; 74(5):2909. PubMed ID: 33884650
    [No Abstract]   [Full Text] [Related]  

  • 88. Letter to Editor: Response to AASLD Editorial/Message from the President.
    Koretz RL; Jakobsen JC; Hauser G; Nikolova D; Gluud C
    Hepatology; 2019 May; 69(5):2300. PubMed ID: 30276829
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Treatment of Hepatitis C: A New Paradigm toward Viral Eradication.
    Squires JE; Balistreri WF
    J Pediatr; 2020 Jun; 221():12-22.e1. PubMed ID: 32446469
    [No Abstract]   [Full Text] [Related]  

  • 90. Moving towards Universal Coverage of Direct-Acting Antiviral Therapies for Hepatitis C Infection in Canada: An Environmental Scan of Canadian Provinces and International Jurisdictions.
    Myers S; Khosa G; Kuo IF; Janzen D; Alessi-Severini S
    J Pharm Pharm Sci; 2018; 21(1s):271s-308s. PubMed ID: 30407908
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Patient reported outcomes as emerging biomarkers in chronic liver disease research.
    Verma M
    J Hepatol; 2020 Jun; 72(6):1215-1216. PubMed ID: 32197799
    [No Abstract]   [Full Text] [Related]  

  • 92. Hepatitis C Virus is Treatable but We Need to Be Sure of a Cure.
    Malnick S; Maor Y
    Isr Med Assoc J; 2021 Dec; 23(12):819-820. PubMed ID: 34954924
    [No Abstract]   [Full Text] [Related]  

  • 93. Hepatitis C reinfection in prisons with broad access to Direct Acting Antiviral treatments.
    Blogg J; Wright T; McGrath C; Clegg J
    Int J Drug Policy; 2020 Mar; 77():102597. PubMed ID: 31952886
    [No Abstract]   [Full Text] [Related]  

  • 94. State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals.
    Kapadia SN; Jeng PJ; Schackman BR; Bao Y
    Clin Infect Dis; 2018 May; 66(10):1618-1620. PubMed ID: 29206910
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon-free direct-acting antiviral combinations? Authors' reply.
    Fourati S; Pawlotsky JM
    Aliment Pharmacol Ther; 2018 Mar; 47(6):849-850. PubMed ID: 29446133
    [No Abstract]   [Full Text] [Related]  

  • 96. IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
    Powderly WG; Naggie S; Kim AY; Vargas HE; Chung RT; Lok AS
    Clin Infect Dis; 2017 Nov; 65(11):1773-1775. PubMed ID: 29020156
    [No Abstract]   [Full Text] [Related]  

  • 97. Editorial: direct-acting antivirals decrease the frequency of diabetes complications in patients with chronic hepatitis C.
    Buchard B; Cacoub P; Pereira B; Abergel A
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1094-1095. PubMed ID: 30920046
    [No Abstract]   [Full Text] [Related]  

  • 98. Insulin resistance and chronic hepatitis C in non-diabetic patients.
    Wiwanitkit V
    Arq Bras Endocrinol Metabol; 2011 Dec; 55(9):727; author reply 728. PubMed ID: 22231979
    [No Abstract]   [Full Text] [Related]  

  • 99. DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist.
    Perrella A; Rinaldi L; Galeota-Lanza A; Izzi A
    Am J Gastroenterol; 2018 Aug; 113(8):1251. PubMed ID: 29686274
    [No Abstract]   [Full Text] [Related]  

  • 100. Hepatitis C and diabetes mellitus: what is the metabolic pathway?
    Perrella A; Borgia G; Reynaud L; Borrelli F; Di Sirio S; Grattacaso S; Perrella O
    Gastroenterology; 2004 Oct; 127(4):1279-80; author reply 1280-1. PubMed ID: 15481022
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.